

# Bridget A Robinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2147442/publications.pdf>

Version: 2024-02-01

87  
papers

4,457  
citations

136740

32  
h-index

106150

65  
g-index

88  
all docs

88  
docs citations

88  
times ranked

6921  
citing authors

#	ARTICLE	IF	CITATIONS
1	Increased Ascorbate Content of Glioblastoma Is Associated With a Suppressed Hypoxic Response and Improved Patient Survival. <i>Frontiers in Oncology</i> , 2022, 12, 829524.	1.3	4
2	Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 583-590.	1.1	0
3	Influence of serum inflammatory cytokines on cytochrome P450 drug metabolising activity during breast cancer chemotherapy: a patient feasibility study. <i>Scientific Reports</i> , 2021, 11, 5648.	1.6	7
4	Is the immunogenicity of PD-1 blocking antibodies a confounding variable in murine studies?. <i>Immunology Letters</i> , 2021, 234, 13-15.	1.1	2
5	Effects of exercise and anti-PD-1 on the tumour microenvironment. <i>Immunology Letters</i> , 2021, 239, 60-71.	1.1	9
6	Limited Association Between Ascorbate Concentrations and Vitamin C Transporters in Renal Cell Carcinoma Cells and Clinical Samples. <i>Cellular Physiology and Biochemistry</i> , 2021, 55, 553-568.	1.1	4
7	Effect of immune modulation on the skeletal muscle mitochondrial exercise response: An exploratory study in mice with cancer. <i>PLoS ONE</i> , 2021, 16, e0258831.	1.1	3
8	Body Mass Index and Outcomes in Breast Cancer Treated With Breast Conservation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 369-376.	0.4	8
9	Low Vitamin C Status in Patients with Cancer Is Associated with Patient and Tumor Characteristics. <i>Nutrients</i> , 2020, 12, 2338.	1.7	12
10	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. <i>PLoS ONE</i> , 2020, 15, e0229290.	1.1	22
11	Long-term results from a series of patients managed with breast conservation surgery and hypofractionated radiotherapy in Christchurch: What is the recurrence rate and how do we detect recurrences. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 852-858.	0.9	1
12	Vitamin C Administration by Intravenous Infusion Increases Tumor Ascorbate Content in Patients With Colon Cancer: A Clinical Intervention Study. <i>Frontiers in Oncology</i> , 2020, 10, 600715.	1.3	15
13	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. , 2020, 15, e0229290.		0
14	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. , 2020, 15, e0229290.		0
15	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. , 2020, 15, e0229290.		0
16	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. , 2020, 15, e0229290.		0
17	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. , 2020, 15, e0229290.		0
18	Effect of post-implant exercise on tumour growth rate, perfusion and hypoxia in mice. , 2020, 15, e0229290.		0

#	ARTICLE	IF	CITATIONS
19	High-grade Glioma – A decade of care in Christchurch. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2019, 63, 665-673.	0.9	4
20	Ascorbate modulates the hypoxic pathway by increasing intracellular activity of the HIF hydroxylases in renal cell carcinoma cells. <i>Hypoxia (Auckland, N Z)</i> , 2019, Volume 7, 17-31.	1.9	24
21	Clinical implications of the genetics of sporadic colorectal cancer. <i>ANZ Journal of Surgery</i> , 2019, 89, 1224-1229.	0.3	25
22	Activation of the hypoxia pathway in breast cancer tissue and patient survival are inversely associated with tumor ascorbate levels. <i>BMC Cancer</i> , 2019, 19, 307.	1.1	48
23	Quantifying BRCA1 and BRCA2 mRNA Isoform Expression Levels in Single Cells. <i>International Journal of Molecular Sciences</i> , 2019, 20, 693.	1.8	1
24	Ischaemic heart disease following conventional and hypofractionated radiation treatment in a contemporary breast cancer series. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2018, 62, 425-431.	0.9	10
25	Complications of curative radiation treatment for early prostate cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e392-e398.	0.7	2
26	Adherence to Adjuvant Endocrine Therapy in Christchurch Women with Early Breast Cancer. <i>Clinical Oncology</i> , 2018, 30, e9-e15.	0.6	22
27	Improved survival for rectal cancer compared to colon cancer: the four cohort study. <i>ANZ Journal of Surgery</i> , 2018, 88, E114-E117.	0.3	25
28	The Association Between Ascorbate and the Hypoxia-Inducible Factors in Human Renal Cell Carcinoma Requires a Functional Von Hippel-Lindau Protein. <i>Frontiers in Oncology</i> , 2018, 8, 574.	1.3	21
29	Investigation of Experimental Factors That Underlie BRCA1/2 mRNA Isoform Expression Variation: Recommendations for Utilizing Targeted RNA Sequencing to Evaluate Potential Spliceogenic Variants. <i>Frontiers in Oncology</i> , 2018, 8, 140.	1.3	15
30	Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. <i>Clinical Colorectal Cancer</i> , 2018, 17, e617-e629.	1.0	54
31	Colorectal multidisciplinary meeting audit to determine patient benefit. <i>ANZ Journal of Surgery</i> , 2017, 87, E173-E177.	0.3	12
32	Rindopemut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1373-1385.	5.1	776
33	First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2017, 18, 1159-1171.	5.1	293
34	Body mass index (BMI): association with clinicopathological factors and outcome of women with newly diagnosed breast cancer in New Zealand. <i>New Zealand Medical Journal</i> , 2017, 130, 46-56.	0.5	4
35	Hypofractionated radiation treatment in early breast cancer: Results in a New Zealand setting. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 248-253.	0.7	1
36	Responding to Acute Care Needs of Patients With Cancer: Recent Trends Across Continents. <i>Oncologist</i> , 2016, 21, 301-307.	1.9	29

#	ARTICLE	IF	CITATIONS
37	Pharmacokinetic and anti-cancer properties of high dose ascorbate in solid tumours of ascorbate-dependent mice. <i>Free Radical Biology and Medicine</i> , 2016, 99, 451-462.	1.3	54
38	SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 1723-1731.	0.8	289
39	Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo <sup>0/0</sup> mice. <i>Cancer Medicine</i> , 2015, 4, 303-314.	1.3	46
40	Phosphohistone H <sup>3</sup> outperforms Ki67 as a marker of outcome for breast cancer patients. <i>Histopathology</i> , 2015, 67, 538-547.	1.6	22
41	Hypofractionated radiation treatment following mastectomy in early breast cancer: The Christchurch experience. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 243-247.	0.9	18
42	Cytomegalovirus and Epstein-Barr Virus in Breast Cancer. <i>PLoS ONE</i> , 2015, 10, e0118989.	1.1	73
43	Marginal effects of glucose, insulin and insulin-like growth factor on chemotherapy response in endothelial and colorectal cancer cells. <i>Oncology Letters</i> , 2014, 7, 311-320.	0.8	16
44	Increased Tumor Ascorbate is Associated with Extended Disease-Free Survival and Decreased Hypoxia-Inducible Factor-1 Activation in Human Colorectal Cancer. <i>Frontiers in Oncology</i> , 2014, 4, 10.	1.3	52
45	Optimal Duration and Timing of Adjuvant Chemotherapy After Definitive Surgery for Ductal Adenocarcinoma of the Pancreas: Ongoing Lessons From the ESPAC-3 Study. <i>Journal of Clinical Oncology</i> , 2014, 32, 504-512.	0.8	351
46	Immunohistochemical analysis of cancer stem cell markers in invasive breast carcinoma and associated ductal carcinoma in situ: relationships with markers of tumor hypoxia and microvasculature. <i>Human Pathology</i> , 2013, 44, 402-411.	1.1	68
47	Professional killer cell deficiencies and decreased survival in pulmonary arterial hypertension. <i>Respirology</i> , 2013, 18, 1271-1277.	1.3	30
48	Sustaining a Biobank Through a Series of Earthquake Swarms: Lessons Learned from our New Zealand Experience. <i>Biopreservation and Biobanking</i> , 2013, 11, 211-215.	0.5	11
49	Dual-Color Fluorescence In Situ Hybridization Reveals an Association of Chromosome 8q22 but Not 8p21 Imbalance with High Grade Invasive Breast Carcinoma. <i>PLoS ONE</i> , 2013, 8, e70790.	1.1	10
50	Renal transplant recipients have elevated frequencies of circulating myeloid-derived suppressor cells. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 402-410.	0.4	49
51	Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks <i>in vitro</i> . <i>Journal of Gene Medicine</i> , 2012, 14, 62-74.	1.4	6
52	Angiogenesis and host immune response contribute to the aggressive character of non-melanoma skin cancers in renal transplant recipients. <i>Histopathology</i> , 2011, 58, 875-885.	1.6	14
53	Association of angiopoietin-2, C-reactive protein and markers of obesity and insulin resistance with survival outcome in colorectal cancer. <i>British Journal of Cancer</i> , 2011, 104, 51-59.	2.9	61
54	A multicenter, randomized, open-label study to assess the steady-state pharmacokinetics of bevacizumab given with either XELOX or FOLFOX-4 in patients with metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1199-1206.	1.1	14

#	ARTICLE	IF	CITATIONS
55	A profile of prognostic and molecular factors in European and Māori breast cancer patients. <i>BMC Cancer</i> , 2010, 10, 543.	1.1	6
56	Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3191-3198.	0.8	370
57	First and subsequent nonmelanoma skin cancers: incidence and predictors in a population of New Zealand renal transplant recipients. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 300-306.	0.4	52
58	Critical Role for Death-Receptor Mediated Apoptotic Signaling in Viral Myocarditis. <i>Journal of Cardiac Failure</i> , 2010, 16, 901-910.	0.7	19
59	Optimizing transfection of primary human umbilical vein endothelial cells using commercially available chemical transfection reagents. <i>Journal of Biomolecular Techniques</i> , 2010, 21, 66-72.	0.8	46
60	Cardiac Cell-specific Apoptotic and Cytokine Responses to Reovirus Infection: Determinants of Myocarditic Phenotype. <i>Journal of Cardiac Failure</i> , 2009, 15, 529-539.	0.7	7
61	Association of chromosome band 8q22 copy number gain with high grade invasive breast carcinomas by assessment of core needle biopsies. <i>Genes Chromosomes and Cancer</i> , 2008, 47, 405-417.	1.5	11
62	Cancer disparities in indigenous Polynesian populations: Māori, Native Hawaiians, and Pacific people. <i>Lancet Oncology</i> , The, 2008, 9, 473-484.	5.1	70
63	Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin. <i>Cancer</i> , 2007, 110, 1945-1950.	2.0	42
64	Cytokeratin KRT8/18 expression differentiates distinct subtypes of grade 3 invasive ductal carcinoma of the breast. <i>Cancer Genetics and Cytogenetics</i> , 2007, 178, 94-103.	1.0	21
65	Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression. <i>BMC Cancer</i> , 2006, 6, 280.	1.1	33
66	Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. <i>Journal of Clinical Oncology</i> , 2006, 24, 4963-4970.	0.8	147
67	Caspase Recruitment Domain-Containing Protein 15 Mutations in Patients with Colorectal Cancer. <i>Cancer Research</i> , 2006, 66, 2532-2535.	0.4	37
68	Nonstructural Protein 1s Is a Determinant of Reovirus Virulence and Influences the Kinetics and Severity of Apoptosis Induction in the Heart and Central Nervous System. <i>Journal of Virology</i> , 2005, 79, 2743-2753.	1.5	30
69	Colorectal cancer treated at Christchurch Hospital, New Zealand: a comparison of 1993 and 1998 cohorts. <i>New Zealand Medical Journal</i> , 2005, 118, U1323.	0.5	3
70	The Christchurch Tissue Bank to support cancer research. <i>New Zealand Medical Journal</i> , 2005, 118, U1735.	0.5	15
71	Caspase Inhibition Protects against Reovirus-Induced Myocardial Injury In Vitro and In Vivo. <i>Journal of Virology</i> , 2004, 78, 11040-11050.	1.5	70
72	The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. <i>Journal of Pathology</i> , 2003, 200, 183-194.	2.1	191

#	ARTICLE	IF	CITATIONS
73	The Effect of Dihydropyrimidine Dehydrogenase Deficiency on Outcomes with Fluorouracil. <i>Toxicological Reviews</i> , 2002, 21, 1-16.	0.5	17
74	Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia. <i>Journal of Pathology</i> , 2002, 198, 502-510.	2.1	88
75	VEGF-B expression in human primary breast cancers is associated with lymph node metastasis but not angiogenesis. <i>Journal of Pathology</i> , 2001, 193, 325-332.	2.1	55
76	Hemorrhagic lymphadenopathy as a presenting feature of primary al amyloidosis. <i>Pathology</i> , 2000, 32, 21-23.	0.3	7
77	Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. <i>Pathology</i> , 1997, 29, 294-299.	0.3	51
78	Clinical Pharmacokinetics and Dose Optimisation of Carboplatin. <i>Clinical Pharmacokinetics</i> , 1997, 33, 161-183.	1.6	126
79	A sequential Bayesian algorithm for dose individualisation of carboplatin. <i>Cancer Chemotherapy and Pharmacology</i> , 1997, 39, 317-326.	1.1	22
80	Pharmacokinetics and efficacy of rectal versus oral sustained-release morphine in cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 31, 251-254.	1.1	41
81	Circadian pharmacokinetics of methotrexate. <i>Cancer Chemotherapy and Pharmacology</i> , 1989, 24, 397-9.	1.1	10
82	CYCLOSPORIN INTERACTION WITH KETOCONAZOLE AND MELPHALAN. <i>Lancet</i> , The, 1982, 320, 1342.	6.3	69
83	Relationships between serosal medium potassium concentration and sodium transport in toad urinary bladder. <i>Journal of Membrane Biology</i> , 1976, 26, 217-238.	1.0	26
84	Relationships between serosal medium potassium concentration and sodium transport in toad urinary bladder. <i>Journal of Membrane Biology</i> , 1976, 26, 239-268.	1.0	42
85	Relationships between serosal medium potassium concentration and sodium transport in toad urinary bladder. <i>Journal of Membrane Biology</i> , 1976, 26, 269-286.	1.0	58
86	The regulation of cellular volume in liver slices. <i>Journal of Physiology</i> , 1974, 238, 279-294.	1.3	38
87	Adjuvant nodal field radiation in resected Stage III melanoma: A single-centre retrospective study in Christchurch, New Zealand. <i>Journal of Medical Imaging and Radiation Oncology</i> , 0, , .	0.9	0